Treating MERS-CoV during an outbreak

The Lancet Infectious Diseases

Volumn 14, Issue 11, 2014, Pages 1030-1031

  Coleman, Christopher M ^a   Frieman, Matthew B ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; RECOMBINANT PROTEIN;

CORONAVIRUS; CORONAVIRUS INFECTION; DRUG DESIGN; DRUG SCREENING; EPIDEMIC; HEALTH CARE AVAILABILITY; HEALTH CARE SYSTEM; HUMAN; IN VITRO STUDY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; NOTE; PUBLIC HEALTH PROBLEM; RNA REPLICATION; SURVIVAL; TIME TO TREATMENT; TREATMENT RESPONSE; VIRUS INFECTION; CORONAVIRUS INFECTIONS; DRUG EFFECTS; FEMALE; MALE;

ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84908295188     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70939-9     Document Type: Note

References (9)

1. de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014, 58:4875-4884.
2. Dyall J, Coleman CM, Hart BJ, et al. Repurposing of clinically developed drugs for treatment of middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014, 58:4885-4893.
3. Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014, published online Sept 30. http://dx.doi.org/10.1016/S1473-3099(14)70920-X.
4. Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D, Thompson R Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res 2014, 6:217-225.
5. Jonsson CB, Hooper J, Mertz G Treatment of hantavirus pulmonary syndrome. Antiviral Res 2008, 78:162-169.
6. Khan SH, Goba A, Chu M, et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res 2008, 78:103-115.
7. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010, 138:116-122.
8. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014, 20:42-46.
9. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E Ribavirin and interferon (IFN)-alpha-2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases. Antivir Ther 2014, published online May 15. 10.3851/IMP2792.